BioAge Labs (BIOA) Cash from Financing Activities (2023 - 2026)

BioAge Labs (BIOA) has 4 years of Cash from Financing Activities data on file, last reported at $123.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 8347.67% year-over-year to $123.7 million; the trailing twelve-month figure through Mar 2026 stood at $136.7 million (down 35.43% YoY), and the FY2025 full-year result was $11.5 million, down 96.99% from the prior year.
• Cash from Financing Activities rose to $123.7 million in Q1 2026, from $16.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q3 2024 to a low of -$2.4 million in Q2 2024.
• A 4-year average of $51.5 million and a median of $7.5 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 100.89% in 2025 and soared 8347.67% in 2026, its largest moves.
• Tracing BIOA's Cash from Financing Activities over 4 years: stood at -$1.0 million in 2023, then soared by 2567.99% to $24.9 million in 2024, then sank by 35.7% to $16.0 million in 2025, then jumped by 672.59% to $123.7 million in 2026.
• Business Quant data shows BIOA's Cash from Financing Activities at $123.7 million in Q1 2026, $16.0 million in Q4 2025, and -$1.5 million in Q3 2025.